Stock BNTX BIONTECH SE
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioNTech SE

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
100.6 USD +1.87% Intraday chart for BioNTech SE +3.76% -4.68%
May. 31 European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower MT
May. 29 BioNTech, CEPI Expand Partnership for mRNA Vaccine Ecosystem in Africa MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,837 16,071 54,764 34,112 22,730 22,386 - -
Enterprise Value (EV) 1 6,318 14,964 53,372 20,449 11,286 9,308 9,916 9,877
P/E ratio -35.6 x 1,112 x 5.72 x 3.72 x 25 x -51.4 x -41.5 x -40.5 x
Yield - - - - - - - -
Capitalization / Revenue 63 x 33.3 x 2.89 x 1.97 x 5.95 x 8.14 x 8.13 x 8.01 x
EV / Revenue 58.2 x 31 x 2.81 x 1.18 x 2.96 x 3.38 x 3.6 x 3.53 x
EV / EBITDA -42.8 x -343 x 3.47 x 1.6 x 12.9 x -10.7 x -10.6 x -10.4 x
EV / FCF -26.6 x -188 x 72.5 x 1.55 x 2.42 x 163 x -12.3 x -13 x
FCF Yield -3.75% -0.53% 1.38% 64.6% 41.3% 0.61% -8.11% -7.67%
Price to Book 13.9 x 11.8 x 4.62 x 1.7 x 1.12 x 1.14 x 1.16 x 1.19 x
Nbr of stocks (in thousands) 226,262 240,786 241,521 243,019 237,716 241,319 - -
Reference price 2 30.22 66.74 226.7 140.4 95.62 92.76 92.76 92.76
Announcement Date 3/31/20 3/30/21 3/30/22 3/27/23 3/20/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 108.6 482.3 18,977 17,311 3,819 2,751 2,754 2,796
EBITDA 1 -147.6 -43.67 15,359 12,766 873.8 -872.9 -937.1 -953.5
EBIT 1 -181.5 -82.42 15,284 12,643 690.4 -1,010 -1,043 -1,030
Operating Margin -167.16% -17.09% 80.54% 73.03% 18.08% -36.73% -37.88% -36.85%
Earnings before Tax (EBT) 1 -179.4 -145.8 15,046 12,954 1,186 -391.2 -565.9 -530.6
Net income 1 -179.1 15.2 10,292 9,434 930.3 -435.1 -571.6 -587.3
Net margin -164.89% 3.15% 54.24% 54.5% 24.36% -15.81% -20.76% -21%
EPS 2 -0.8500 0.0600 39.63 37.77 3.830 -1.804 -2.234 -2.291
Free Cash Flow 1 -237.1 -79.51 735.7 13,214 4,667 57.02 -804.6 -757.7
FCF margin -218.37% -16.48% 3.88% 76.34% 122.19% 2.07% -29.21% -27.1%
FCF Conversion (EBITDA) - - 4.79% 103.51% 534.06% - - -
FCF Conversion (Net income) - - 7.15% 140.06% 501.62% - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/31/20 3/30/21 3/30/22 3/27/23 3/20/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 5,532 6,375 3,196 3,461 4,278 1,277 167.7 895.3 1,479 187.6 147 529.9 1,983 208 181.8
EBITDA 1 4,726 - - 2,421 3,322 685.8 - 114.4 605 -468.9 -660 -290 824 - -
EBIT 1 4,700 4,753 2,210 2,388 3,293 654.4 -563.3 73.1 526.2 -507.2 -656.3 -383.7 579.6 -709.2 -729.7
Operating Margin 84.95% 74.56% 69.13% 68.98% 76.97% 51.25% -335.9% 8.16% 35.58% -270.36% -446.55% -72.41% 29.23% -341% -401.48%
Earnings before Tax (EBT) 1 4,714 5,018 2,319 2,444 3,173 707.7 -412.2 227.4 663.2 -331.8 -502.5 -235.7 764.7 -522.6 -527.7
Net income 1 3,166 3,699 1,672 1,785 2,279 502.2 -190.4 160.6 457.9 -315.1 -450.4 -265.5 685.4 -522.6 -527.7
Net margin 57.23% 58.02% 52.31% 51.57% 53.26% 39.33% -113.54% 17.94% 30.96% -167.96% -306.47% -50.1% 34.57% -251.26% -290.36%
EPS 2 12.18 14.24 6.450 6.980 9.260 2.050 -0.7900 0.6700 1.900 -1.310 -2.064 -1.494 2.992 -1.796 -2.039
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 3/30/22 5/9/22 8/8/22 11/7/22 3/27/23 5/8/23 8/7/23 11/6/23 3/20/24 5/6/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 519 1,107 1,391 13,663 11,445 13,078 12,469 12,508
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -237 -79.5 736 13,214 4,667 57 -805 -758
ROE (net income / shareholders' equity) -47.1% 1.63% 155% 59.1% 4.62% -2.89% -2.9% -3.51%
ROA (Net income/ Total Assets) -24.7% 0.98% 113% 48.2% 4.02% -1.99% -2.66% -4.02%
Assets 1 725.3 1,558 9,075 19,555 23,143 21,913 21,517 14,591
Book Value Per Share 2 2.180 5.680 49.00 82.50 85.20 81.70 80.10 78.30
Cash Flow per Share 2 -0.9400 -0.0500 3.430 55.80 22.60 4.640 0.6200 0.0300
Capex 1 38.6 66 128 329 249 443 353 315
Capex / Sales 35.54% 13.69% 0.67% 1.9% 6.53% 16.1% 12.81% 11.26%
Announcement Date 3/31/20 3/30/21 3/30/22 3/27/23 3/20/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
92.76 EUR
Average target price
103.1 EUR
Spread / Average Target
+11.16%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
INSMED INCORPORATED Stock Insmed Incorporated
+77.64% 8.87B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BNTX Stock
  4. Financials BioNTech SE